Merck lowers mid-term healthcare outlook after recent drug failures
German science and technology company Merck lowered mid-term targets for its Life Sciences and Healthcare businesses, ...
Merck's RSV antibody for infants effective in reducing some types of infections in study
Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...
Merck & Co. (MRK): Strong Growth Driven by Keytruda and New Vaccine Approvals
We recently published a list of 10 Best Medical Stocks to Buy Now. In this article, we are going to take a look at where ...
Merck antibody reduces RSV-related disease, hospitalizations in trial
Detailed data from a Phase 2b/3 study of Merck’s treatment clesrovimab should support the company’s efforts to win approval ...
Germany's Merck open to more M&A for its Life Science division
German science and technology group Merck is open to more acquisitions for its Life Science business after announcing in May ...
BioSpace5h
Merck, Pfizer Tout Promising Respective Data in RSV With High Rates of Prevention
Merck’s investigational antibody clesrovimab demonstrated more than 60% effectiveness in reducing some types of respiratory ...
Merck Is At Support And Should Go Higher (Technical Analysis)
Merck's recent decline is due to reduced profit guidance and FDA decisions, but shares are at a support level. Read why I ...
Is Merck & Co., Inc. (MRK) the Most Promising Long-Term Stocks According to Hedge Funds?
We recently compiled a list of 10 Most Promising Long-Term Stocks According to Hedge Funds. In this article, we will look at ...
Business Wire20h
Merck’s Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus (RSV) Preventative Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease …
Clesrovimab (MK-1654), an Investigational RSV Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and ...
Merck RSV therapy cuts respiratory infections by 60% in infants
Merck's (MRK) monoclonal antibody clesrovimab shows cuts RSV infections by 60% in infants, with a strong safety profile. Read ...
Merck KGaA Boss Is Scoffing at the Obesity Hype: Leader Q&A
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Exelixis, Merck Sign Zanzalintinib Development Collaboration
Exelixis, an Alameda, Calif., oncology company, and Rahway, N.J., drugmaker Merck said they also plan a Phase 1/2 trial and two Phase 3 studies of zanzalintinib in combination with Merck's Welireg in ...